APOE and amyloidosis: However, aducanumab was linked to amyloid-related imaging abnormalities (ARIA), specifically vasogenic edema (ARIA-E), occurring in a dose-dependent manner in 3–41% of recipients, especially in carriers of the APOE ε4 allele.